title: Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
abstract: We studied the stability of freeze-dried therapeutic protein formulations over a range of initial concentrations (from 40 to 160 mg/mL) and employed a variety of formulation strategies (including buffer-free freeze dried formulations, or BF-FDF). Highly concentrated, buffer-free liquid formulations of therapeutic monoclonal antibodies (mAbs) have been shown to be a viable alternative to conventionally buffered preparations. We considered whether it is feasible to use the buffer-free strategy in freeze-dried formulations, as an answer to some of the known drawbacks of conventional buffers. We therefore conducted an accelerated stability study (24 weeks at 40 °C) to assess the feasibility of stabilizing freeze-dried formulations without "classical" buffer components. Factors monitored included pH stability, protein integrity, and protein aggregation. Because the protein solutions are inherently self-buffering, and the system's buffer capacity scales with protein concentration, we included highly concentrated buffer-free freeze-dried formulations in the study. The tested formulations ranged from "fully formulated" (containing both conventional buffer and disaccharide stabilizers) to "buffer-free" (including formulations with only disaccharide lyoprotectant stabilizers) to "excipient-free" (with neither added buffers nor stabilizers). We evaluated the impacts of varying concentrations, buffering schemes, pHs, and lyoprotectant additives. At the end of 24 weeks, no change in pH was observed in any of the buffer-free formulations. Unbuffered formulations were found to have shorter reconstitution times and lower opalescence than buffered formulations. Protein stability was assessed by visual inspection, sub-visible particle analysis, protein monomer content, charge variants analysis, and hydrophobic interaction chromatography. All of these measures found the stability of buffer-free formulations that included a disaccharide stabilizer comparable to buffer-based formulations, especially at protein concentrations up to and including 115 mg/mL.
authors.affiliation: Boehringer Ingelheim Pharma GmbH & Co. KG, Corporate Division Biopharmaceuticals, Process Science, Protein Science, Biberach an der Riss, Germany. Electronic address: patrick.garidel@boehringer-ingelheim.com.
authors.forename: Patrick
authors.initials: P
authors.lastname: Garidel
authors.affiliation: Boehringer Ingelheim Pharma GmbH & Co. KG, Corporate Division Biopharmaceuticals, Process Science, Protein Science, Biberach an der Riss, Germany.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Pevestorf
authors.affiliation: Boehringer Ingelheim Pharma GmbH & Co. KG, Corporate Division Biopharmaceuticals, Process Science, Protein Science, Biberach an der Riss, Germany.
authors.forename: Sven
authors.initials: S
authors.lastname: Bahrenburg
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry*; D002021:Buffers; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D004339:Drug Compounding / Q000379:methods; D004356:Drug Storage; D005079:Excipients / Q000737:chemistry*; D005240:Feasibility Studies; D005612:Freeze Drying; D006863:Hydrogen-Ion Concentration; D057927:Hydrophobic and Hydrophilic Interactions; D055550:Protein Stability; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D002021:Buffers; D005079:Excipients
keywords: Buffer-free; Freeze-drying; Lyophilization; Monoclonal antibody; Protein stability; Self-buffering formulation; pH buffering